Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study
Toxins · 2025
DOI: 10.3390/toxins17070349 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Toxins, 2025. Verfasst von Juthapa Pongklaokam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Melanosis, Botulinum Toxins, Type A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hugel Inc., located at 61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do, 24203, Republic of Korea., Hugel Inc..
Abstract (Originalsprache)
Background
Melasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits.
Objective
We sought to evaluate the efficacy and safety of two intradermal dilutions of Letibotulinum toxin A (LetiBoNT-A) in Thai patients with melasma.
Methods
In this randomized, double-blind, split-face study, 30 participants aged 32–62 years received a single intradermal injection of LetiBoNT-A, with 20 units administered per cheek. A 1:5 dilution was injected on one side of the face, and a 1:10 dilution was injected on the contralateral side. Outcomes were evaluated over a 6-month period using the Hemi-modified Melasma Area and Severity Index (Hemi-mMASI), VISIA® brown spot analysis, and quantitative assessments of skin texture.
Results
Both dilutions significantly improved Hemi-mMASI scores (1:5, p = 0.043; 1:10, p = 0.002) and brown spots (1:5, p = 0.002; 1:10, p < 0.001). The 1:10 dilution showed earlier and more sustained improvements. Subgroup analysis revealed greater reductions in Hemi-mMASI scores among patients with telangiectatic melasma, particularly with the 1:10 dilution, though they were not statistically significant. Additionally, the 1:10 dilution significantly reduced pore volume, pore area, and sebum levels. One case of transient facial asymmetry was reported with the 1:5 dilution.
Conclusions
LetiBoNT-A is a safe and effective adjunct in melasma treatment. The 1:10 dilution offered superior clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
- Department of Dermatology, Research Institute for Tropical Medicine, 9002 Research, Mutinlupa 1781, Philippines.
ORCID-Profile: Juthapa Pongklaokam, Woraphong Manuskiatti, Rungsima Wanitphakdeedecha, Woramate Bhorntarakcharoen, Thanya Techapichetvanich
Förderung
- Hugel Inc., located at 61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do, 24203, Republic of Korea.
- Hugel Inc.
Zitieren
APA
Pongklaokam, J., Manuskiatti, W., Wanitphakdeedecha, R., Maneeprasopchoke, P., Thongjaroensirikul, P., Nokdhes, Y., Abad-Constantino, R. M. R., Bhorntarakcharoen, W., Sittiwanaruk, S., & Techapichetvanich, T. (2025). Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study. Toxins. https://doi.org/10.3390/toxins17070349
Vancouver
Pongklaokam J, Manuskiatti W, Wanitphakdeedecha R, Maneeprasopchoke P, Thongjaroensirikul P, Nokdhes Y, et al. Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study. Toxins. 2025. doi:10.3390/toxins17070349
BibTeX
@article{Pongklaokam2025,
author = {Pongklaokam, Juthapa and Manuskiatti, Woraphong and Wanitphakdeedecha, Rungsima and Maneeprasopchoke, Pitchaya and Thongjaroensirikul, Panwadee and Nokdhes, Yanin and Abad-Constantino, Rona Maria R and Bhorntarakcharoen, Woramate and Sittiwanaruk, Sariya and Techapichetvanich, Thanya},
title = {Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17070349}
}
EUVIMED